Definiens to Host International Symposium for Tissue Phenomics®

Summit to Present Advancements in Tissue Phenomics, Immunoprofiling, Immuno-Oncology and Big Data

MUNICH--()--Definiens, the pioneer in Tissue Phenomics solutions for diagnostics development, has announced that registration is now open for the company’s upcoming conference, The International Symposium for Tissue Phenomics, from April 26-27, 2016 in Cambridge, Massachusetts.

Tissue Phenomics, the use of unique tissue signatures correlated to genetic or patient outcome data to develop precise and powerful tissue-based diagnostics, continues to be a key driver in the growth of personalized medicine in oncology. This year’s Symposium will focus on new advancements and important work being done in the space, specifically “The Future of Cancer Dx,” as well tissue-based immunoprofiling, big data and data integration, and digital pathology and diagnostics in immuno-oncology.

The symposium will feature presentations and discussions by leading distinguished researchers and speakers, including:

  • Joseph Beecham, Nanostring Technologies, Inc.
  • Carlo Bifulco, Providence Health & Services, Inc.
  • Gerd Binnig, Definiens AG
  • Peter Caie, University of St. Andrews
  • Manfred Dietel (Chair), Charité
  • Belma Dogdas, Merck & Co., Inc.
  • Bernhard Fox (Chair), Providence Health & Services, Inc.
  • Jerôme Galon, Inserm
  • James Gulley, NIH
  • Michael Hehenberger, IBM
  • Ron Herbst, MedImmune
  • Jeff Hodgin, University of Michigan Medical School
  • Dirk Jäger, NCT Heidelberg
  • Trevor McKee, Princess Margaret Cancer Centre
  • Holger Moch, University of Zurich
  • Bob Silverman, Gilde Healthcare

“The annual Symposium has become a central meeting for discussion on cancer companion diagnostics and personalized medicine,” said Thomas Heydler, CEO, Definiens. “Significant advancements are being made with Tissue Phenomics, and this event, which brings together some of the greatest minds in the industry, is critical to continuing the dialogue, collaboration and education needed for the progress of tissue-based diagnostics and immune-oncology.”

The symposium will take place from April 26-27, 2016 at the Hotel Marlowe in Cambridge, Massachusetts. Register online at http://www.cvent.com/d/sfqk2w.

For more information, please contact Lina Willis, global marketing and conference manager at lwillis@definiens.com.

About Definiens

Definiens is the pioneering provider of Tissue Phenomics® solutions for biomarker and companion diagnostics development. Definiens’ technology empowers smarter tissue-based diagnostics by leveraging quantitative tissue readouts and other big data sources. By enabling the development of powerful and precise assays for patient stratification and clinical trial enrollment, Definiens aims to dramatically improve patient outcomes. Definiens' Tissue Phenomics approach was awarded the 2013 Frost and Sullivan Company of the Year Award for Global Tissue Diagnostics and Pathology Imaging. For more information, please visit: www.definiens.com.

Contacts

Media:
Affect
Jonathan Moll, +1 212-398-9680
jmoll(at)affect.com

Contacts

Media:
Affect
Jonathan Moll, +1 212-398-9680
jmoll(at)affect.com